New Report Available: Japan Pharmaceuticals & Healthcare Report Q2 2015

From: Fast Market Research, Inc.
Published: Tue Feb 17 2015


Japan's healthcare system will come under increasing financial strain due to the ageing population and the high use of patented medicines. This provides an impetus for the government to use cost containment measures including policies to encourage the uptake of generic drug medicines, posing a downside risk for R&D-based pharmaceutical companies

Headline Expenditure Projections

* Pharmaceuticals: JPY11,239bn (USD107bn) in 2014 to JPY11,490bn (USD96bn) by 2015 with a year-on-year growth of 2.2% in local currency terms and -10.5% in USD terms. The contraction in the US dollar amount is due to the strengthening of the dollar against the yen.
* Healthcare: JPY50,661bn (USD482bn) in 2014 to JPY52,266bn (USD436bn) in 2015 with a year-on-year growth of 3.2% in local currency terms and-9.7% in USD terms. The lower US dollar amount is driven by the weakening of the yen against the dollar.

Full Report Details at
- http://www.fastmr.com/prod/956874_japan_pharmaceuticals_healthcare_report_q2_2015.aspx?afid=301

Risk/Reward Index

Japan's continues to be ranked as the most attractive region according to our Pharmaceutical Risk/Reward Index, scoring 74.5 out of 100 in Q215, significantly ahead of peers such as Australia (67) and South Korea (66.2) as well as the region's average at 52.9. This is driven by the country's high market expenditure scoring (18.0 out of 20.0) as well as a high spending per capita score of (10.8 out of 12.0). However, dragging down the country's score includes a declining population (population growth score of 1.0 out of 5.0). In addition, we highlight that the country's score has been lowered from Q115 due to the weakness in the Japanese Yen, which translates into a lower value returns in US dollars.

Key Trends And Developments

* In January 2015, the Ministry of Health Labour and Welfare unveiled draft plans to reform the country's health insurance programme. Scheduled to be implemented from the fiscal year of 2015 through to 2018, these reforms include abolishing in principle special measures that lower the health insurance premium payments for...

The Japan Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Japan Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Japan pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Japan, to test other views - a key input for successful budgeting and strategic business planning in the Japanese pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bulgaria Pharmaceuticals & Healthcare Report Q2 2015
- South Korea Pharmaceuticals & Healthcare Report Q2 2015
- Peru Pharmaceuticals & Healthcare Report Q2 2015
- Nigeria Pharmaceuticals & Healthcare Report Q2 2015
- Mexico Pharmaceuticals & Healthcare Report Q2 2015
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »